Eli Lilly Initiates Phase 1 Clinical Trial for New Oral Weight-Loss Drug LY4086940

▎Armstrong

On April 25, 2025, Eli Lilly registered another oral weight-loss innovative drug, LY4086940, for clinical trials on the Clinicaltrials.gov website.

This Phase I clinical trial plans to enroll 165 subjects and is expected to be completed in April 2026.

LY4086940 is administered orally.

Weight loss is a key therapeutic area for Eli Lilly, with several innovative drugs in the early clinical stages.

Summary

Eli Lilly has taken a comprehensive lead in the iterative competition of GLP-1 and, in doing so, ascended to become the world's most valuable pharmaceutical company. Tirzepatide is currently the most potent product on the market, while its next-generation small-molecule GLP-1 has successfully advanced to phase III clinical trials for diabetes. The GGG triple-target drug is also in phase III clinical trials. As GLP-1 continues to gain momentum, companies like Eli Lilly and Novo Nordisk have begun actively exploring new mechanisms for weight-loss drugs.